APOE4 Gene

APOE (apolipoprotein E) is a gene that produces a protein involved in lipid transport and metabolism throughout the body. The APOE gene has three common variants: APOE2, APOE3 (the most common), and APOE4. Having one or two copies of the APOE4 variant significantly increases the risk of developing late-onset Alzheimer's disease.

Approximately 25% of the population carries one copy of APOE4 (heterozygous carriers), and about 2-3% carry two copies (homozygous carriers). Heterozygous APOE4 carriers have approximately 2-3 times the lifetime risk of Alzheimer's compared to people with two copies of APOE3. Homozygous APOE4 carriers have approximately 8-12 times the risk — a risk high enough that it effectively confers near-deterministic Alzheimer's risk by late life in some analyses.

APOE4 influences Alzheimer's risk through several biological mechanisms: it impairs amyloid clearance (APOE4 is less efficient than APOE3 at facilitating amyloid removal from the brain), promotes amyloid aggregation, disrupts lipid metabolism in neurons and astrocytes, and increases neuroinflammation. It also influences cardiovascular disease risk, which has its own cognitive implications.

APOE4 status is clinically relevant for several reasons. It substantially modifies the baseline risk interpretation for a person with cognitive concerns. It influences eligibility and risk profiles for anti-amyloid treatments — APOE4 carriers, particularly homozygous carriers, have substantially elevated risk of ARIA (brain swelling and microhemorrhages) with lecanemab and donanemab, and treatment decisions must weigh this elevated risk.

APOE4 testing is commercially available through direct-to-consumer genetic testing. The decision to test is personal and involves considering what you would do with the information and how you would manage the psychological implications. Many people with APOE4 status never develop Alzheimer's; conversely, many people who develop Alzheimer's do not carry APOE4. APOE4 is a risk modifier, not a deterministic predictor.

Importantly, APOE4 does not change the recommended risk-modification strategy. The lifestyle interventions that reduce Alzheimer's risk — cardiovascular risk management, sleep quality, exercise, cognitive engagement — are the same for APOE4 carriers and non-carriers. Knowing your status can motivate prioritizing these factors, but the factors themselves matter regardless.